Dipeptidyl-Peptidase IV Inhibitors

• 

  Subject Areas on Research

  • A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. 
  • Association Between Sitagliptin Use and Heart Failure Hospitalization and Related Outcomes in Type 2 Diabetes Mellitus: Secondary Analysis of a Randomized Clinical Trial. 
  • CD26 inhibition enhances allogeneic donor-cell homing and engraftment after in utero hematopoietic-cell transplantation. 
  • Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. 
  • Corrections needed to 2016 ESC and AHA guidelines on heart failure. 
  • Cost-effectiveness of diabetes treatment sequences to inform step therapy policies. 
  • Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight. 
  • Diabetes medication regimens and patient clinical characteristics in the national patient-centered clinical research network, PCORnet. 
  • Dipeptidyl-peptidase-4 inhibitors and pancreatic cancer: a cohort study. 
  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. 
  • Effect of Sitagliptin on Kidney Function and Respective Cardiovascular Outcomes in Type 2 Diabetes: Outcomes From TECOS. 
  • Effect of race on the glycaemic response to sitagliptin: Insights from the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). 
  • Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial. 
  • Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes. 
  • Impact of metformin use on the cardiovascular effects of dipeptidyl peptidase-4 inhibitors: An analysis of Medicare claims data from 2007 to 2015. 
  • In CV disease, GLP-1 RAs and SGLT2 inhibitors reduce CV mortality. 
  • Inhibition of Dipeptidyl Peptidase-4 Impairs Ventricular Function and Promotes Cardiac Fibrosis in High Fat-Fed Diabetic Mice. 
  • Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA. 
  • Metformin Use May Moderate the Effect of DPP-4 Inhibitors on Cardiovascular Outcomes. 
  • New combination treatments in the management of diabetes: focus on sitagliptin-metformin. 
  • Newer second-line glucose-lowering drugs versus thiazolidinediones on cirrhosis risk among older US adult patients with type 2 diabetes. 
  • Pancreatic Safety of Sitagliptin in the TECOS Study. 
  • Plasma levels of DPP4 activity and sDPP4 are dissociated from inflammation in mice and humans. 
  • Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk. 
  • Re-adjudication of the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS) with study-level meta-analysis of hospitalization for heart failure from cardiovascular outcomes trials with dipeptidyl peptidase-4 (DPP-4) inhibitors. 
  • Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). 
  • Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS. 
  • Sodium-glucose co-transporter-2 inhibitor use and risk of lower-extremity amputation: Evolving questions, evolving answers. 
  • Sulfonylurea Prescribing Patterns After the Introduction of DPP-4 Inhibitors and GLP-1 Receptor Agonists. 
  • The dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus: cardiovascular safety. 
  • The incretins and beta-cell health: contrasting glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 as a path to understand islet function in diabetes. 
  • The role of dysregulated glucagon secretion in type 2 diabetes. 
  • Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes. 
  • Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. 
  • Understanding the type 2 diabetes mellitus and cardiovascular disease risk paradox. 
  • What if gut hormones aren't really hormones: DPP-4 inhibition and local action of GLP-1 in the gastrointestinal tract.